[Chemotherapy and immunotherapy of metastatic malignant melanomas].
Prognosis in metastatic malignant melanoma is poor because of chemo and radiotherapy resistance. However, some drugs, such as dacarbazine, cisplatinum or fotemustine, a new nitrosourea, have produced a response rate of more than 20%. Combining these drugs increases response rate to 30-40%. Immunotherapy by interferon-alpha 2 shows about 15-20% response rate but interleukin-2 would be more effective especially in combination with cisplatinum and interferon-alpha 2 with 50% response and long survival after cessation of treatment.
Benhammouda
A
A
SOMPS, Hôpital de la Salpêtrière, Paris.
Auclerc
G
G
Coeffic
D
D
Weil
M
M
Nizri
D
D
Soubrane
C
C
Banzet
P
P
Khayat
D
D
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary / Q000628:therapy*
Chimiothérapie et immunothérapie des mélanomes malins métastatiques.